Patent · US Active

Complement inhibitors and uses thereof

US8911735B2 · kind B2 · utility

3Cited by
7References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 15, 2012
Grant dateDec 16, 2014
Priority date
Expiry dateJun 15, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/55
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologs, analogs and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.